Deal Details

Follow-on Offering

Healthcare

Follow-on Offering

Summary

Baird served as a co-manager on the offering

About

Tandem Diabetes Care, Inc. (“Tandem”, the “Company”) (NASDAQ:TNDM) recently completed a follow-on offering of 4,035,085 shares, which includes 526,315 shares solely to cover over-allotments, at a price of $28.50 per share, generating gross proceeds of $115.0 million. Tandem intends to use the net proceeds from this offering to satisfy all or a portion of its indebtedness to Capital Royalty Partners under the Term Loan Agreement, for working capital and other general corporate purposes.

Tandem Diabetes Care, Inc. is a medical device company with an innovative approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company believes its competitive advantage is rooted in the unique consumer-focused approach, and the incorporation of modern and innovative technology into the product offerings. Tandem’s manufacturing and sales activities primarily focus on its flagship product, the t:slim™ X2 insulin pump, which is based on its proprietary technology platform. The simple-to-use t:slim X2 is the smallest durable insulin pump available, and the only pump currently available in the United States that is capable of remote feature updates, which positions the Company well to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. By delivering innovative hardware and software solutions, as well as best-in-class customer support, Tandem aims to improve and simplify the lives of people with diabetes and their healthcare providers. Tandem is headquartered in San Diego, California.

Healthcare

Follow-on Offering